Olanzapine Augmentation Therapy in Treatment-resistant Depression: a Double-blind Placebo-controlled Trial

• Status: Terminated
• Trial end date: 2009-12-01
• Target enrollment: 0
• Participant gender: All

Summary

60 patients with major depression will be treated with 10 mg Olanzapine or Placebo for 2 weeks. In case of response (reduction of depressive symptoms)the study will be continued for further 60 days.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital Freiburg
• Treatments: Olanzapine

Criteria

Inclusion Criteria:

• major depression without psychotic features

• therapy resistance (2 courses of antidepressants from different classes for more than 3 weeks in adequate dose

• HAM-D score greater/equal than 17

• age 18-65

Exclusion Criteria:

• bipolar disorder

• active alcohol or illicit drug use

• female with ineffective contraception

• severe medical conditions, epilepsy

• psychotic features